Show simple item record

dc.contributor.authorMiguel, Sara de 
dc.contributor.authorDomenech Lucas, Mirian 
dc.contributor.authorGonzalez-Camacho, Fernando 
dc.contributor.authorSempere, Julio 
dc.contributor.authorVicioso-Perez, Maria Dolores 
dc.contributor.authorSanz, Juan Carlos
dc.contributor.authorGarcía Comas, Luis
dc.contributor.authorArdanuy, Carmen
dc.contributor.authorFenoll, Asuncion 
dc.contributor.authorYuste, Jose Enrique 
dc.date.accessioned2020-10-28T14:03:22Z
dc.date.available2020-10-28T14:03:22Z
dc.date.issued2020-09-29
dc.identifier.citationClin Infect Dis . 2020 Sep 29;ciaa1483.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11254
dc.description.abstractIntroduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused by vaccine serotypes in children providing herd protection to the elderly group. However, the emergence of non-vaccine serotypes is of great concern worldwide. This study includes national laboratory data from invasive pneumococcal disease (IPD) cases affecting pediatric and adult population during 2009-2019. The impact of implementing different vaccine strategies for immunocompetent adults comparing Spanish regions using PCV13 vs regions using PPV23 vaccine was also analyzed for 2017-2019. The overall reductions of IPD cases by PCV13 serotypes in children and adults were 88% and 59% respectively during 2009-2019 with a constant increase of serotype 8 in adults since 2015. IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to 52% in 2019. In children, serotype 24F was the most frequent in 2019 whereas in adults, serotypes 3 and 8 accounted for 36% of IPD cases. Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish regions reduced up to 25% and 11% respectively the IPD cases by PCV13 serotypes, showing a decrease of serotype 3 when PCV13 was used. Use of PCV13 in children has shown a clear impact in pneumococcal epidemiology reducing the burden of IPD in children but also in adults by herd protection although the increase of serotype 8 in adults is worrisome. Vaccination with PCV13 in immunocompetent adults seems to control IPD cases by PCV13 serotypes including serotype 3.es_ES
dc.description.sponsorshipThis work was supported by Ministerio de Economía, Industria y Competitividad (MINECO) [grant SAF2017-83388] and internal funding fromes_ES
dc.language.isoenges_ES
dc.publisherOxford University Press es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshStreptococcus pneumoniae es_ES
dc.subject.meshIPDes_ES
dc.subject.meshSerotypeses_ES
dc.subject.meshPCV13es_ES
dc.subject.meshPPV23es_ES
dc.titleNationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID32990303es_ES
dc.identifier.doi10.1093/cid/ciaa1483es_ES
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1537-6591
dc.relation.publisherversionhttps://doi.org/10.1093/cid/ciaa1483es_ES
dc.identifier.journalClinical infectious diseases : an official publication of the Infectious Diseases Society of Americaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-83388es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional